Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. Key executives, including CEO Lonnel Coats, CFO Jeffrey L. Wade, and CMO Craig Granowitz, will engage in a moderated discussion on April 19th at 10:15 AM ET.
The event will be streamed live, and the recording will be accessible for two weeks post-event on the company’s website. Lexicon is focused on developing innovative medicines through its Genome5000™ program, which has identified over 100 protein targets for various diseases.
With a commitment to transforming lives, Lexicon has one marketed medicine and is actively developing candidates for conditions like heart failure and diabetes.
- None.
- None.
THE WOODLANDS, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023.
Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion on Wednesday, April 19th, at 10:15 am ET.
The webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcast will be available for two weeks following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor Inquiries:
Carrie Siragusa
Lexicon Pharmaceuticals, Inc.
csiragusa@lexpharma.com
For Media Inquiries:
Alina Kolomeyer
Lexicon Pharmaceuticals, Inc.
akolomeyer@lexpharma.com
FAQ
When is Lexicon Pharmaceuticals participating in the Needham Virtual Healthcare Conference?
What time is Lexicon Pharmaceuticals' discussion during the Needham Conference?
Who are the key executives participating in the Lexicon Pharmaceuticals' conference discussion?
Where can I find the webcast of Lexicon Pharmaceuticals' conference discussion?
What is the focus of Lexicon Pharmaceuticals' research and development?
